Cytosorbents Crp (CTSO)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $15.28M
Last updated: Nov 17, 2026 at 4:10 PM ET
Cytosorbents Crp (CTSO) Statistics
Cytosorbents Crp (CTSO) has a market cap of $15.28M and an enterprise value of $28.11M. It kept -48.94% of revenue as net income over the last 12 months. Its net debt of $12.83M equals 83.94% of its market cap.
Total Valuation
Enterprise value is 83.94% above the market cap, as debt exceeds cash.
| Market Cap | $15.28M |
|---|---|
| Enterprise Value | $28.11M |
| Latest price (Nov 17, 2026) | $4.52 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 0.4x. Its year-end P/S ranged from 21.5x to 291.1x from 2016 to 2025.
| P/S Ratio | 0.4x |
|---|---|
| Forward P/S | 0.4x |
Price Statistics
The stock is down 65.76% over 52 weeks and trades 5.64% below its 50-day average.
| Beta (1Y) | 1.19 |
|---|---|
| 52-Week Change | -65.76% |
| 1-Month Change | -8.87% |
| 3-Month Change | -36.52% |
| 6-Month Change | -52.17% |
| 5-Year Change | -96.15% |
| 10-Year Change | -96.15% |
| Total Return (1Y) | -65.76% |
| Total Return (3Y CAGR) | -41.68% |
| Total Return (5Y CAGR) | -47.49% |
| Return vs SPY (1Y) | -75.20% |
| Max Drawdown (1Y) | -81.72% |
| Max Drawdown (3Y) | -91.68% |
| Sharpe Ratio (1Y) | -1.04 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $4.79 |
| 200-Day Average | $8.98 |
| 52-Week Range | $2.84 to $17.00 |
| RSI (14 Days) | 45.8 |
| Average Volume (20 Days) | 29.10K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.66x current liabilities.
| Current Ratio | 0.66x |
|---|---|
| Quick Ratio | 0.50x |
Returns and Efficiency
Return on invested capital is -74.25% over the last 12 months, against a 5-year average of -69.62%.
| Return on Assets (ROA) | -47.98% |
|---|---|
| Return on Invested Capital (ROIC) | -74.25% |
| Return on Capital Employed (ROCE) | -111.20% |
| ROA (5Y Average) | -39.37% |
| ROIC (5Y Average) | -69.62% |
| Asset Turnover | 0.87x |
| Inventory Turnover | 2.59x |
| Receivables Turnover | 5.34x |
| Cash Conversion Cycle | 121 days |
Scores
CTSO has an Altman Z-Score of -12.28, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -12.28 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $37.22M over the last 12 months is up 3.07% from the 12 months before.
| Revenue | $37.22M |
|---|---|
| Revenue Growth (YoY) | +3.07% |
| Gross Profit | $26.65M |
| Operating Income | -$12.93M |
| Pretax Income | -$18.61M |
| Net Income | -$18.21M |
| EBIT | -$15.50M |
| Reported EPS (TTM) | -$0.82 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
| Cash and Equivalents | $4.41M |
|---|---|
| Total Debt | $17.24M |
| Net Debt | $12.83M |
| Net Debt Per Share | $4.08 |
| Working Capital | -$8.29M |
| Shareholder Equity | -$751.00K |
| Tangible Book Value | -$3.62M |
| Total Assets | $37.96M |
| Total Liabilities | $38.71M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $150.00K of capital spending, operating cash flow left -$9.30M of free cash flow.
| Operating Cash Flow | -$9.15M |
|---|---|
| Capital Expenditures | $150.00K |
| Free Cash Flow | -$9.30M |
| FCF Per Share | -$2.95 |
| Depreciation and Amortization | $2.55M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -34.74%, against a 5-year average of -66.47%.
| Gross Margin | 71.61% |
|---|---|
| Operating Margin | -34.74% |
| Pretax Margin | -50.02% |
| Net Margin | -48.94% |
| EBIT Margin | -41.64% |
| FCF Margin | -24.98% |
| Gross Margin (5Y Average) | 69.24% |
| Operating Margin (5Y Average) | -66.47% |
| Net Margin (5Y Average) | -65.18% |
Growth
Revenue grew 2.23% a year over 3 years.
| Revenue Growth (3Y CAGR) | +2.23% |
|---|---|
| Revenue Growth (5Y CAGR) | -2.00% |
| Book Value Per Share Growth (2Y CAGR) | -57.72% |
| Tangible Book Per Share Growth (2Y CAGR) | -71.53% |
Dividends and Yields
CTSO does not pay a dividend. Its free cash flow yield is -65.50%.
| FCF Yield | -65.50% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-20 reverse split on Sep 8, 2026.
| Last Split Date | Sep 8, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 10 similar companies, CTSO has the 9th highest P/S and the 4th highest ROIC.
P/S RatioPeer median 1.7x
ROICPeer median -189.69%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +11.65%
| P/S Ratio | 0.4x vs 1.7x median |
|---|---|
| ROIC | -74.25% vs -189.69% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +3.07% vs +11.65% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.16% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +9.16% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CTSO
What is CTSO's market cap?
Cytosorbents Crp has a market cap of $15.28M. Its enterprise value, which adds debt and subtracts cash, is $28.11M.
How many shares of CTSO are outstanding?
Cytosorbents Crp has 3.14M shares outstanding. The count is up 0.32% from a year earlier.
Does CTSO pay a dividend?
No. Cytosorbents Crp does not pay a dividend.
How much debt does CTSO have?
Cytosorbents Crp has $17.24M of total debt and $4.41M of cash and equivalents, a net debt position of $12.83M.
CTSO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors